ANAC Arctos NorthStar Acquisition Corp. Class A

DELISTED - Anacor Pharmaceuticals Inc is a United States-based biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company's product candidates include topically administered dermatologic compounds-tavaborole (formerly AN2690), a topical antifungal for the treatment of onychomycosis, and AN2728, a topical anti-inflammatory for the treatment of atopic dermatitis and psoriasis. In addition, it is engaged in the development of other wholly-owned clinical product candidates, AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. The Company's clinical pipeline also includes internally developed topical and systemic boron-based compounds in development.

$9.77  +0.01 (0.10%)
As of 09/17/2021 16:00:02 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Financials
Industry:  Shell Companies
Index country:  USA
Country of incorporation:  
IPO date:  04/15/2021
Outstanding shares:  31,625,000
Average volume:  46,447
Market cap:   $308,343,750
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   -19.12
PB ratio:   1.06
PS ratio:   0.00
Return on equity:   -3.18%
Net income %:   -52.83%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy